Boston Scientific (BSX) has been the leader in sales of stents, those little mess tubes that keep arteries open. Recent studies show that the devices are more dangerous than most doctors had believed. That has hurt sales and the BSX shares.
Now Abbott (ABT) is taking a stent of its own (the Xience) to the FDA. Some data show it may be better than the flagship Boston Scientific product call Taxus. If further review bears this out, BSX is in for another beating.
A JP Morgan analyst was recently quoted by The Associated Press as saying "The data presented by Abbott does show that Xience is statistically superior to Taxus, which is the market leader."
BSX shares are down 2.5% today to $12.37. If the FDA loves the new Abbott product, the stock may go lower.
Douglas A. McIntyre
Get Ready To Retire (Sponsored)
Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.